STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior

Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activati...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Okabe, Naota [verfasserIn] Fujiwara, Masachika [verfasserIn] Tachibana, Keisei [verfasserIn] Tanaka, Ryota [verfasserIn] Kondo, Haruhiko [verfasserIn] Kamma, Hiroshi [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	Thymic epithelial tumors JAK/STAT pathway STAT3 Cyclin D1 JAK3

Anmerkung:	© The Japanese Association for Thoracic Surgery 2021

Übergeordnetes Werk:	Enthalten in: The Japanese journal of thoracic and cardiovascular surgery - Tōkyō : Springer Japan, 1998, 69(2021), 11 vom: 01. Juni, Seite 1482-1491
Übergeordnetes Werk:	volume:69 ; year:2021 ; number:11 ; day:01 ; month:06 ; pages:1482-1491

Links:	Volltext

DOI / URN:	10.1007/s11748-021-01655-9

Katalog-ID:	SPR045232504

Internformat


LEADER	01000caa a22002652 4500
001	SPR045232504
003	DE-627
005	20230519194715.0
007	cr uuu---uuuuu
008	211007s2021 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s11748-021-01655-9 \|2 doi
035			\|a (DE-627)SPR045232504
035			\|a (SPR)s11748-021-01655-9-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
100	1		\|a Okabe, Naota \|e verfasserin \|4 aut
245	1	0	\|a STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Japanese Association for Thoracic Surgery 2021
520			\|a Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis.
650		4	\|a Thymic epithelial tumors \|7 (dpeaa)DE-He213
650		4	\|a JAK/STAT pathway \|7 (dpeaa)DE-He213
650		4	\|a STAT3 \|7 (dpeaa)DE-He213
650		4	\|a Cyclin D1 \|7 (dpeaa)DE-He213
650		4	\|a JAK3 \|7 (dpeaa)DE-He213
700	1		\|a Fujiwara, Masachika \|e verfasserin \|4 aut
700	1		\|a Tachibana, Keisei \|e verfasserin \|4 aut
700	1		\|a Tanaka, Ryota \|e verfasserin \|4 aut
700	1		\|a Kondo, Haruhiko \|e verfasserin \|4 aut
700	1		\|a Kamma, Hiroshi \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t The Japanese journal of thoracic and cardiovascular surgery \|d Tōkyō : Springer Japan, 1998 \|g 69(2021), 11 vom: 01. Juni, Seite 1482-1491 \|w (DE-627)539545104 \|w (DE-600)2381600-4 \|x 1863-2092 \|7 nnns
773	1	8	\|g volume:69 \|g year:2021 \|g number:11 \|g day:01 \|g month:06 \|g pages:1482-1491
856	4	0	\|u https://dx.doi.org/10.1007/s11748-021-01655-9 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 69 \|j 2021 \|e 11 \|b 01 \|c 06 \|h 1482-1491

Indexfelder

author_variant	n o no m f mf k t kt r t rt h k hk h k hk
matchkey_str	article:18632092:2021----::ttatvtoityieihlatmrcreainihyln1
hierarchy_sort_str	2021
publishDate	2021
allfields	10.1007/s11748-021-01655-9 doi (DE-627)SPR045232504 (SPR)s11748-021-01655-9-e DE-627 ger DE-627 rakwb eng 610 ASE Okabe, Naota verfasserin aut STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Japanese Association for Thoracic Surgery 2021 Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis. Thymic epithelial tumors (dpeaa)DE-He213 JAK/STAT pathway (dpeaa)DE-He213 STAT3 (dpeaa)DE-He213 Cyclin D1 (dpeaa)DE-He213 JAK3 (dpeaa)DE-He213 Fujiwara, Masachika verfasserin aut Tachibana, Keisei verfasserin aut Tanaka, Ryota verfasserin aut Kondo, Haruhiko verfasserin aut Kamma, Hiroshi verfasserin aut Enthalten in The Japanese journal of thoracic and cardiovascular surgery Tōkyō : Springer Japan, 1998 69(2021), 11 vom: 01. Juni, Seite 1482-1491 (DE-627)539545104 (DE-600)2381600-4 1863-2092 nnns volume:69 year:2021 number:11 day:01 month:06 pages:1482-1491 https://dx.doi.org/10.1007/s11748-021-01655-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 69 2021 11 01 06 1482-1491
spelling	10.1007/s11748-021-01655-9 doi (DE-627)SPR045232504 (SPR)s11748-021-01655-9-e DE-627 ger DE-627 rakwb eng 610 ASE Okabe, Naota verfasserin aut STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Japanese Association for Thoracic Surgery 2021 Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis. Thymic epithelial tumors (dpeaa)DE-He213 JAK/STAT pathway (dpeaa)DE-He213 STAT3 (dpeaa)DE-He213 Cyclin D1 (dpeaa)DE-He213 JAK3 (dpeaa)DE-He213 Fujiwara, Masachika verfasserin aut Tachibana, Keisei verfasserin aut Tanaka, Ryota verfasserin aut Kondo, Haruhiko verfasserin aut Kamma, Hiroshi verfasserin aut Enthalten in The Japanese journal of thoracic and cardiovascular surgery Tōkyō : Springer Japan, 1998 69(2021), 11 vom: 01. Juni, Seite 1482-1491 (DE-627)539545104 (DE-600)2381600-4 1863-2092 nnns volume:69 year:2021 number:11 day:01 month:06 pages:1482-1491 https://dx.doi.org/10.1007/s11748-021-01655-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 69 2021 11 01 06 1482-1491
allfields_unstemmed	10.1007/s11748-021-01655-9 doi (DE-627)SPR045232504 (SPR)s11748-021-01655-9-e DE-627 ger DE-627 rakwb eng 610 ASE Okabe, Naota verfasserin aut STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Japanese Association for Thoracic Surgery 2021 Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis. Thymic epithelial tumors (dpeaa)DE-He213 JAK/STAT pathway (dpeaa)DE-He213 STAT3 (dpeaa)DE-He213 Cyclin D1 (dpeaa)DE-He213 JAK3 (dpeaa)DE-He213 Fujiwara, Masachika verfasserin aut Tachibana, Keisei verfasserin aut Tanaka, Ryota verfasserin aut Kondo, Haruhiko verfasserin aut Kamma, Hiroshi verfasserin aut Enthalten in The Japanese journal of thoracic and cardiovascular surgery Tōkyō : Springer Japan, 1998 69(2021), 11 vom: 01. Juni, Seite 1482-1491 (DE-627)539545104 (DE-600)2381600-4 1863-2092 nnns volume:69 year:2021 number:11 day:01 month:06 pages:1482-1491 https://dx.doi.org/10.1007/s11748-021-01655-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 69 2021 11 01 06 1482-1491
allfieldsGer	10.1007/s11748-021-01655-9 doi (DE-627)SPR045232504 (SPR)s11748-021-01655-9-e DE-627 ger DE-627 rakwb eng 610 ASE Okabe, Naota verfasserin aut STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Japanese Association for Thoracic Surgery 2021 Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis. Thymic epithelial tumors (dpeaa)DE-He213 JAK/STAT pathway (dpeaa)DE-He213 STAT3 (dpeaa)DE-He213 Cyclin D1 (dpeaa)DE-He213 JAK3 (dpeaa)DE-He213 Fujiwara, Masachika verfasserin aut Tachibana, Keisei verfasserin aut Tanaka, Ryota verfasserin aut Kondo, Haruhiko verfasserin aut Kamma, Hiroshi verfasserin aut Enthalten in The Japanese journal of thoracic and cardiovascular surgery Tōkyō : Springer Japan, 1998 69(2021), 11 vom: 01. Juni, Seite 1482-1491 (DE-627)539545104 (DE-600)2381600-4 1863-2092 nnns volume:69 year:2021 number:11 day:01 month:06 pages:1482-1491 https://dx.doi.org/10.1007/s11748-021-01655-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 69 2021 11 01 06 1482-1491
allfieldsSound	10.1007/s11748-021-01655-9 doi (DE-627)SPR045232504 (SPR)s11748-021-01655-9-e DE-627 ger DE-627 rakwb eng 610 ASE Okabe, Naota verfasserin aut STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Japanese Association for Thoracic Surgery 2021 Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis. Thymic epithelial tumors (dpeaa)DE-He213 JAK/STAT pathway (dpeaa)DE-He213 STAT3 (dpeaa)DE-He213 Cyclin D1 (dpeaa)DE-He213 JAK3 (dpeaa)DE-He213 Fujiwara, Masachika verfasserin aut Tachibana, Keisei verfasserin aut Tanaka, Ryota verfasserin aut Kondo, Haruhiko verfasserin aut Kamma, Hiroshi verfasserin aut Enthalten in The Japanese journal of thoracic and cardiovascular surgery Tōkyō : Springer Japan, 1998 69(2021), 11 vom: 01. Juni, Seite 1482-1491 (DE-627)539545104 (DE-600)2381600-4 1863-2092 nnns volume:69 year:2021 number:11 day:01 month:06 pages:1482-1491 https://dx.doi.org/10.1007/s11748-021-01655-9 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 69 2021 11 01 06 1482-1491
language	English
source	Enthalten in The Japanese journal of thoracic and cardiovascular surgery 69(2021), 11 vom: 01. Juni, Seite 1482-1491 volume:69 year:2021 number:11 day:01 month:06 pages:1482-1491
sourceStr	Enthalten in The Japanese journal of thoracic and cardiovascular surgery 69(2021), 11 vom: 01. Juni, Seite 1482-1491 volume:69 year:2021 number:11 day:01 month:06 pages:1482-1491
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Thymic epithelial tumors JAK/STAT pathway STAT3 Cyclin D1 JAK3
dewey-raw	610
isfreeaccess_bool	false
container_title	The Japanese journal of thoracic and cardiovascular surgery
authorswithroles_txt_mv	Okabe, Naota @@aut@@ Fujiwara, Masachika @@aut@@ Tachibana, Keisei @@aut@@ Tanaka, Ryota @@aut@@ Kondo, Haruhiko @@aut@@ Kamma, Hiroshi @@aut@@
publishDateDaySort_date	2021-06-01T00:00:00Z
hierarchy_top_id	539545104
dewey-sort	3610
id	SPR045232504
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR045232504</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519194715.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">211007s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11748-021-01655-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR045232504</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11748-021-01655-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Okabe, Naota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Japanese Association for Thoracic Surgery 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thymic epithelial tumors</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">JAK/STAT pathway</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">STAT3</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclin D1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">JAK3</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujiwara, Masachika</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tachibana, Keisei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Ryota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kondo, Haruhiko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kamma, Hiroshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The Japanese journal of thoracic and cardiovascular surgery</subfield><subfield code="d">Tōkyō : Springer Japan, 1998</subfield><subfield code="g">69(2021), 11 vom: 01. Juni, Seite 1482-1491</subfield><subfield code="w">(DE-627)539545104</subfield><subfield code="w">(DE-600)2381600-4</subfield><subfield code="x">1863-2092</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:69</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:11</subfield><subfield code="g">day:01</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:1482-1491</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11748-021-01655-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">69</subfield><subfield code="j">2021</subfield><subfield code="e">11</subfield><subfield code="b">01</subfield><subfield code="c">06</subfield><subfield code="h">1482-1491</subfield></datafield></record></collection>
author	Okabe, Naota
spellingShingle	Okabe, Naota ddc 610 misc Thymic epithelial tumors misc JAK/STAT pathway misc STAT3 misc Cyclin D1 misc JAK3 STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior
authorStr	Okabe, Naota
ppnlink_with_tag_str_mv	@@773@@(DE-627)539545104
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1863-2092
topic_title	610 ASE STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior Thymic epithelial tumors (dpeaa)DE-He213 JAK/STAT pathway (dpeaa)DE-He213 STAT3 (dpeaa)DE-He213 Cyclin D1 (dpeaa)DE-He213 JAK3 (dpeaa)DE-He213
topic	ddc 610 misc Thymic epithelial tumors misc JAK/STAT pathway misc STAT3 misc Cyclin D1 misc JAK3
topic_unstemmed	ddc 610 misc Thymic epithelial tumors misc JAK/STAT pathway misc STAT3 misc Cyclin D1 misc JAK3
topic_browse	ddc 610 misc Thymic epithelial tumors misc JAK/STAT pathway misc STAT3 misc Cyclin D1 misc JAK3
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	The Japanese journal of thoracic and cardiovascular surgery
hierarchy_parent_id	539545104
dewey-tens	610 - Medicine & health
hierarchy_top_title	The Japanese journal of thoracic and cardiovascular surgery
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)539545104 (DE-600)2381600-4
title	STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior
ctrlnum	(DE-627)SPR045232504 (SPR)s11748-021-01655-9-e
title_full	STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior
author_sort	Okabe, Naota
journal	The Japanese journal of thoracic and cardiovascular surgery
journalStr	The Japanese journal of thoracic and cardiovascular surgery
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	1482
author_browse	Okabe, Naota Fujiwara, Masachika Tachibana, Keisei Tanaka, Ryota Kondo, Haruhiko Kamma, Hiroshi
container_volume	69
class	610 ASE
format_se	Elektronische Aufsätze
author-letter	Okabe, Naota
doi_str_mv	10.1007/s11748-021-01655-9
dewey-full	610
author2-role	verfasserin
title_sort	stat3 activation in thymic epithelial tumors: correlation with cyclin d1, jak3, and clinical behavior
title_auth	STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior
abstract	Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis. © The Japanese Association for Thoracic Surgery 2021
abstractGer	Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis. © The Japanese Association for Thoracic Surgery 2021
abstract_unstemmed	Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis. © The Japanese Association for Thoracic Surgery 2021
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702
container_issue	11
title_short	STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior
url	https://dx.doi.org/10.1007/s11748-021-01655-9
remote_bool	true
author2	Fujiwara, Masachika Tachibana, Keisei Tanaka, Ryota Kondo, Haruhiko Kamma, Hiroshi
author2Str	Fujiwara, Masachika Tachibana, Keisei Tanaka, Ryota Kondo, Haruhiko Kamma, Hiroshi
ppnlink	539545104
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s11748-021-01655-9
up_date	2024-07-03T14:39:10.177Z
_version_	1803569122704883712
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR045232504</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519194715.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">211007s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s11748-021-01655-9</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR045232504</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s11748-021-01655-9-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Okabe, Naota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Japanese Association for Thoracic Surgery 2021</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Objectives Thymic epithelial tumors are the most common adult mediastinal tumors; however, their growth mechanism remains relatively unknown. Among the JAK/STAT pathway-related proteins, which control various intracellular events, STAT3 is deeply involved in cell proliferation. Constitutive activation of STAT3 and the resulting overexpression of cyclin D1 have been confirmed in various tumors, but have not been thoroughly investigated in thymic epithelial tumors. In this study, we immunohistochemically examined STAT3 activation, cyclin D1 expression, and JAK3 activation in thymic epithelial tumors and statistically analyzed their correlation with clinicopathological features. Methods Formalin-fixed paraffin-embedded specimens of 94 thymic epithelial tumors surgically resected at Kyorin University Hospital between 2005 and 2018 were included in this study. pSTAT3, cyclin D1, and pJAK3 were immunohistochemically examined, and the correlation with histology, Masaoka stage, and survival time was statistically analyzed. Results Cyclin D1 was found to be significantly overexpressed in the STAT3-activated group. This phenomenon was associated with histology and Masaoka stage. JAK3 was also activated in thymic epithelial tumors; however, JAK3 and STAT3 activation were not always correlated. Using survival time analysis, the STAT3-activated group, cyclin D1-expressed group, and JAK3-activated group had significantly lower progression-free survival times than those for both the non-activated and non-expressed groups. Conclusions STAT3 activation may promote cyclin D1 overexpression in thymic epithelial tumors, and intracellular signaling pathways other than JAK3 may be involved in STAT3 activation. STAT3 activation, cyclin D1 overexpression, and JAK3 activation are biomarker candidates that indicate clinically poor prognosis.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Thymic epithelial tumors</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">JAK/STAT pathway</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">STAT3</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cyclin D1</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">JAK3</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fujiwara, Masachika</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tachibana, Keisei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tanaka, Ryota</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kondo, Haruhiko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kamma, Hiroshi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The Japanese journal of thoracic and cardiovascular surgery</subfield><subfield code="d">Tōkyō : Springer Japan, 1998</subfield><subfield code="g">69(2021), 11 vom: 01. Juni, Seite 1482-1491</subfield><subfield code="w">(DE-627)539545104</subfield><subfield code="w">(DE-600)2381600-4</subfield><subfield code="x">1863-2092</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:69</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:11</subfield><subfield code="g">day:01</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:1482-1491</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s11748-021-01655-9</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">69</subfield><subfield code="j">2021</subfield><subfield code="e">11</subfield><subfield code="b">01</subfield><subfield code="c">06</subfield><subfield code="h">1482-1491</subfield></datafield></record></collection>
score	7.400522

Nicht das Richtige dabei?

Schreiben Sie uns!

STAT3 activation in thymic epithelial tumors: correlation with cyclin D1, JAK3, and clinical behavior

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?